Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 110 matches for

Q: What kind of biosciences careers event features being an actress, being a cool kid, twin babies, presenting to empty lecture theatres, offices with no toilets for women, and mentorship schemes that don’t work? A: The BioEscalator’s International Women’s Day 2026 seminar.

Audience members seated at round tables in discussion during the BioEscalator International Women’s Day event.

Let’s just get married – the story of an acquisition

"We decided to skip the engagement and just get married" – that’s how Hutano Diagnostics’ CEO Atherton Mutombwera describes his company’s acquisition by EDx Medical in 2023. The meeting of minds between him and the purchaser’s CEO, Dr Mike Hudson, was the culmination of six years of hard work by Atherton developing multiplex lateral flow diagnostics based on aptamers.

Theolytics awarded €8 million in Horizon Europe 2025 grant funding to advance phase 2 study of THEO-260 in ovarian cancer

Pending final negotiations, the grant will fund up to 20 patients in the OCTOPOD-IV Phase 2a expansion study of THEO-260 in platinum-resistant ovarian cancer. The competitive funding award highlights Theolytics’ innovative science and strong clinical development plan. The application is coordinated with several major international clinical centres and world-class partners.

Nucleome Therapeutics appoints experienced biotech executive Dr Michelle Morrow as Chief Scientific Officer

Dr Morrow brings deep expertise in immunology, oncology, and pharmacology, with a strong track record of advancing innovative pipelines from discovery to the clinic. The appointment reflects growing momentum at Nucleome following the nomination of the first preclinical development candidate, lead candidate NTP464, which is progressing towards IND-enabling studies.

OMass Therapeutics appoints Jonathan Montagu as Chair of the Board of Directors

OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announced updates to its Board of Directors, including the appointment of Jonathan Montagu, Chief Executive Officer and co-founder of HotSpot Therapeutics, as Board Chair.

Enara Bio enters 2026 with Dark Antigen licensing to Boehringer Ingelheim, appointment of Chief Medical Officer and plans to advance DARKFOX T-cell engager into First-in-Human studies

Boehringer Ingelheim has licensed additional Dark Antigens from various tumour types, enhancing Enara’s eligibility for milestone payments under their collaboration. Scott Drutman, M.D., Ph.D. has been appointed as Chief Medical Officer, bringing valuable expertise in translational medicine and immuno-oncology. Enara’s ENA101, a bispecific T-cell engager targeting the DARKFOX antigen, is planned to enter First-in-Human studies in 2026, while the company continues expanding its EDAPT discovery platform to include cell-surface Dark Antigens.

Certis Belchim and Moa sign strategic collaboration deal

Netherlands-based company becomes Moa's third major commercial partner in 18 months.

Nucleome Therapeutics nominates first preclinical development candidate

First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic inflammatory diseases. Evolution of Nucleome’s non-coding genetics platform reveals further groundbreaking insights into disease areas of high unmet need.

Abbott to acquire Exact Sciences

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments.

Prior Labs and Oxford Cancer Analytics partner to advance liquid biopsy and clinical decision making in lung disease

Prior Labs is collaborating with Oxford Cancer Analytics (OXcan) to apply TabPFN to high-clinical-need lung diseases, focusing on more accurate differentiation across complex disease stages.

Ochre Bio completes human liver functional genomics and single-cell datasets in partnership with GSK

Ochre Bio, a biotechnology company developing RNA therapeutics for chronic liver disease, today announced the successful completion of the research phase of its collaboration with GSK, delivering two comprehensive functional genomics and single-cell human liver datasets.

PepGen announces issuance of U.S. Patent for proprietary PGN-EDODM1 molecule

The Composition of Matter patent covers the Company’s novel PGN-EDODM1 molecule and serves as a cornerstone of its expanding patent portfolio.

Nucleome Therapeutics founder Professor James Davies and Oxford University publish paper in prestigious journal Cell

Groundbreaking research using Nucleome MCC technology reveals complex structure of DNA inside living cells at base pair resolution for the first time, pioneering a new approach to identify new drug targets from human genetics.

Enara Bio’s DARKFOX discovery propels ENA101, the first ever bispecific T Cell engager targeting a cancer-specific dark antigen, into IND-enabling studies

Enara Bio, a biopharmaceutical company pioneering the discovery of novel Dark Antigens® and the development of bispecific T cell engagers for solid tumours, will unveil its newly discovered cancer-specific target DARKFOX™ as the first in a new category of validated Dark Antigens in an oral presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 2025 annual meeting. SITC 2025 is being held on November 5-9 in National Harbor, MD.

Partnership with CyanoCapture Ltd to develop bionanotechnology for targeted drug delivery

The University of Liverpool rand CyanoCapture Ltd are joining forces to develop the next generation of carboxysome-based targeted drug delivery systems, exploiting unique traits found in fast-growing cyanobacteria.

Alethio Therapeutics launches with new CEO and Chair to advance two targeted medicines for Myeloproliferative Neoplasms (Chronic Blood Cancers)

Leveraging deep scientific and clinical expertise in MPNs, the company aims to drive a pipeline of disease-modifying precision therapies that selectively target disease-driving cells. Progress is being made with AT-01, a first-in-class antibody-drug conjugate (ADC) program, which has strong preclinical validation and is advancing toward IND/CTA-enabling studies anticipated to start in the first half of 2026. Additionally, AT-02 expands the ADC portfolio by targeting mutant CALR, a key driver mutation in MPNs. The leadership and board have been strengthened with the appointments of Dr. Rohit Batta as CEO and Mike Grey as Chair.

MediMabBio secures KRW 25.6B in Series B funding to advance pipeline and global partnerships

MediMabBio has successfully raised KRW 25.6B (USD $17M) in its Series B financing round. The newly secured capital will be used to expand strategic global partnerships for accelerated business development and the advancement of follow-on programs.

MediMabBio Wins 1st Place at Japan’s “Innovation Tiger 2025”

MediMabBio won first place at Innovation Tiger 2025, a global biotech startup competition held at Shonan iPark in Japan. The final round featured 16 companies selected from 79 applicants across Korea, Japan, and Taiwan.

Theolytics appoints experienced medical oncologist Matilde Saggese, MD, as Chief Medical Officer

Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260. THEO-260, is currently being investigated in patients with platinum-resistant ovarian cancer.

PepGen Announces Highest Mean Splicing Correction Reported in DM1 Patients

53.7% mean splicing correction observed following a single 15 mg/kg dose of PGN-EDODM1, with all patients showing an improvement in splicing. PGN-EDODM1 was generally well-tolerated at 15 mg/kg, with drug-related adverse events mild or moderate in severity

PepGen Announces Pricing of $100M Public Offering

PepGen currently intends to use the net proceeds from this offering to fund its ongoing research and clinical development efforts, including the FREEDOM-DM1 and FREEDOM2-DM1 clinical trials, as well as for working capital and other general corporate purposes.

Load More

Similar stories